Lake Street Maintains Buy on Tandem Diabetes Care, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Brooks O'Neil maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $60 to $75.
May 22, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lake Street analyst Brooks O'Neil maintains a Buy rating on Tandem Diabetes Care and raises the price target from $60 to $75.
The raised price target from $60 to $75 and the maintained Buy rating by Lake Street analyst Brooks O'Neil is a positive signal for investors, likely leading to a short-term increase in TNDM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100